# Saint Luke's Health System

Organization · id `cardio:org-saint-luke-s-health-system` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ROR record 0127qs140](<https://ror.org/0127qs140>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. Matched to ROR record 0127qs140 by an exact name.

## The registry's words

- Sponsor name: Saint Luke's Health System
- Sponsor class: OTHER
- ROR name: Saint Luke's Health System

## Connected pages

- Sponsors: Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure (`cardio:ct-nct02653482`)
- Sponsors: Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (`cardio:ct-nct03030235`)
- Sponsors: Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (`cardio:ct-nct03515083`)

## Provenance

Content hash: 23ac3a0177c4e75fa85f7c6c0fa8ce9cb9b4c7e94612f3ecd41b503b5a537292
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
